Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema OLN324 ...

Novartis has announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function decline in adults with immunoglobulin A nephropathy (IgAN). The ...